Globus Medical Inc Class A (GMED)

Over the past six months, Globus Medical announced preliminary sales numbers for Q4 and full year 2025 in January 2026, signaling aggressive growth and market share expansion. In February 2026, Globus Medical reported its Q4 2025 earnings, beating consensus estimates. Management provided 2026 adjusted EPS guidance of $4.40–$4.50 and nearly 10% revenue growth. Despite positive earnings and guidance, the stock experienced a significant drop of over 22% on May 9, 2025, following the Q1 2025 earnings report where non-GAAP EPS and revenue missed consensus estimates. As of March 30, 2026, the stock price was $83.78.

Globus Medical exhibits distinct seasonal tendencies based on 14 years of historical data. Historically, November has been the strongest month for GMED, with an average return of 5.90% and a win rate of 64%. Conversely, September tends to be the weakest month, averaging a -1.59% return. The company has also noted "quarterly seasonality and longer sales cycles dampened robotic sales" in past reports.

Globus Medical, Inc. (GMED) is a publicly traded medical device company focused on designing, developing, and commercializing products to improve the quality of life for patients with musculoskeletal disorders. The company's products are categorized into musculoskeletal solutions, including implantable devices and biologics, and enabling technologies, featuring advanced imaging, navigation, and robotics systems. The majority of Globus Medical's revenue is generated from its musculoskeletal solutions products.

Globus Medical operates in 64 countries, with more than half of its revenue earned in the United States. The company has a presence in numerous countries, including Australia, Austria, Belgium, Brazil, Denmark, Finland, Germany, India, Ireland, Italy, Netherlands, Norway, Poland, South Africa, Sweden, Switzerland, and the United Kingdom, in addition to its US headquarters.

Globus Medical aims to solve unmet clinical needs and deliver procedurally integrated solutions with leading-edge enabling technologies to improve patient care. The company has been actively launching new products, with over 10 new products introduced in 2023 alone. One significant event impacting the company's reputation and market perception in the past year was its merger with NuVasive, Inc., which became effective on September 1, 2023. However, the company also faced a class action lawsuit investigation initiated in May 2025 concerning potential violations of federal securities laws.

Institutional investors are the dominant force in Globus Medical's ownership structure, holding a substantial majority of the Class A common stock. As of April 2025, institutional investors collectively owned 82.91% of the Class A common stock, with mutual funds alone holding 70.11%. As of March 27, 2026, Globus Medical, Inc. had 682 institutional owners and shareholders holding a total of 115,503,561 shares. Insider holdings accounted for a smaller portion at 0.82% in April 2025.